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SUSCEPTIBILITY TO ANTIFUNGAL AGENTS OF CANDIDA 
SPP. FROM BLOOD AND FECES COLLECTED IN NOVI SAD 
IN 3-YEAR PERIOD (2008-2010)
ABSTRACT: Candidemia is an important emerging nosocomial infection in patients 
with risk factors. Candida species from nonsterile sites can give insight into the character-
istics of strains that may cause invasive disease.
The aim of this study was to evaluate antifungal susceptibility of Candida blood and 
fecal isolates in Novi Sad, Vojvodina.
During a 3-year period (2008 to 2010), 424 isolates of Candida spp. were collected, 
30 bloodstream isolates and 394 strains from fecal samples. In vitro susceptibility of these 
isolates to five antifungal agents was established using commercial ATB FUNGUS 3 (Bio-
Mérieux).
Predominant species was Candida albicans (6 isolates from blood and 269 from feces). 
Resistance to one or more antifungal agents was less common in Candida albicans (3.63%) 
than in other species (24.83%). Resistance to itraconazole was the most commonly found in 
both groups of isolates, 9.64% strains from feces and 20% from blood samples. Twelve 
isolates were multiply resistant, usually to fluconazole, itraconazole, and voriconazole. Re-
sistance to amphotericine B was extremely rare.
Although resistance to antimycotics of Candida spp. is rare at present, continued 
surveillance of antifungal susceptibility is necessary in order to monitor trends, and to 
choose the right empiric therapy.
KEY WORDS: antifungal susceptibility, candidemia, Candida spp.
INTRODUCTION 
Candidemia is an important emerging nosocomial infection in patients 
with risk factors. In the last two decades an increase of bloodstream infections 
caused by Candida species (Candida spp.) has been documented, with a con-
sequent rise in related mortality and prolonged hospitalizations (Tu lu m og lu 
S. et al., 2009). Risk factors for development of candidemia are: immunocom-
promised host, immunosuppressive therapy and neutropenia, intensive care 
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units patients, central venous catheters, parenteral nutrition, and the long-term 
use of broad-spectrum antibacterial drugs (Ta k a k u r a  S. et al., 2006).
Candida spp. at multiple nonsterile sites often suggests colonization but 
these strains also may cause invasive disease. Candida spp. from nonsterile 
sites can also give insight into the characteristics of strains that cause the dis-
ease (Ta sic  S. et al., 2008).
The variability in the susceptibility of clinical isolates to antifungal drugs 
emphasizes the importance of performing species identification and antifun-
gal susceptibility testing (M it rov ic  S. M. et al., 2007).
There are data which show that Candida albicans (C. albicans) main-
tains excellent susceptibility to all antifungal agents, but many non-albicans 
species have increased resistance to antifungal drugs over the past decades. 
(Tu lu mog lu  S. et al., 2009)
There are differences in species distribution and antifungal susceptibility 
profiles and it is important to obtain such information for each geographic 
area (Muel le r  F. M. et al., 2000)
The aim of this study was to assess the antifungal susceptibility profiles 
in both strains of Candida spp. associated with systemic disease and fecal 
isolates.
MATERIAL AND METHODS
In the Center for Microbiology of Institute for Public Health of Vojvo-
dina during a 3-year period, from January 2008 to December 2010, a total of 
424 isolates of Candida spp. were collected, 30 bloodstream isolates and 394 
strains from fecal samples.
Blood samples were collected in sterile conditions into 30 ml culture 
medium for BacT/Alert- BioMérieux. The bottles which were positive after 
incubation at 37º C for 2-5 days were transferred to blood agar and Sabouraud 
Dextrose Agar and incubated 24 hours at 35ºC, and next 24 hours at 25ºC. 
Fecal samples were inoculated to Sabouraud Dextrose Agar and incu-
bated 24 hours at 35ºC, and next 24 hours at 25ºC.
Colonies of Candida spp. were identified by examination of their micro-
scopic and macroscopic features. Candida albicans was identified by the ap-
plication of germination tube test in human serum. Species identification was 
confirmed by API 20C (BioMérieux) or Vitek2 (BioMérieux) for resistant 
blood isolates of Candida spp.
In vitro susceptibility of all isolates to five antifungal agents was estab-
lished using commercial ATB FUNGUS 3 (BioMérieux, France) that enables 
the determination of the susceptibility to five antifungal agents under condi-
tions similar to the reference method for micro-dilution according to EUCAST 
(European Committee on Antibiotic Susceptibility Testing) and CLSI (Clini-
cal and Laboratory Standards Institute) recommendations. The results ob-
tained give a MIC (Minimal inhibitory concentration) for amphotericin B 
(AMB), fluconazole (FCA), itraconazole (ITR), voriconazole (VRC) and/or 21
classify the strain as Sensitive (S), Intermediate (I) or Resistant (R) flucyto-
sine (5FC).
The interpretative breakpoints were proposed by the manufacturer of the 
test. Fluconazole MICs ≤ 8.0 mg/L were considered susceptible and ≥ 64 
mg/L were considered resistant, with the exception of C. krusei, which is 
considered inherently resistant to fluconazole, regardless of the MIC value. 
Isolates showing itraconazole MICs ≤ 0.125 mg/L and voriconazole ≤ 1 mg/L 
were classified as susceptible and those with MICs ≥ 1 mg/L for itraconazole 
and ≥ 4 mg/L for voriconazole as resistant. Although interpretative break-
points for amphotericine B have not yet been established, isolates showing 
MIC of ≥ 2 mg/L suggest resistance.
RESULTS
From 30 blood isolates and 394 fecal isolates predominant species was 
Candida albicans, 269 from fecal samples and 6 strains from blood (in hemo-
cultures Candida spp. was more common). Resistance to one or more antifun-
gal agents was less common in Candida albicans (3.63%) than in other Can-
dida species (24.83%).
From total of 269 fecal isolates of Candida albicans 259 (96.28%) were 
susceptible to all antimicrobial drugs tested. Ten isolates (3.72%) had one or 
more resistance markers. One resistance marker had 4 strains, they were re-
sistant to itraconazole, one was resistant to fluconazole and itraconazole, and 
five isolates had 3 markers and were resistant to fluconazole, itraconazole, 
and voriconazole. In Candida spp. (non-albicans) 24.80% had resistance mark-
ers, 24 (19.20%) strains with one marker, 1 (0.80%) with 2 markers, 5 (4.00%) 
with 3 markers and 1 (0.80%) strain with 4 resistance markers (Table 1).
Resistance to itraconazole was the most commonly found in both groups of 
fecal isolates, 3.72% of Candida albicans strains and 22.40% of Candida spp.
Tab. 1 – Resistance types of Candida isolates from feces (comparative data for Candida albicans 
and Candida spp.) 
Number of 
resistance 
markers
Resistance types 
of Candida 
albicans
Number (%) 
of isolates
Number of 
resistance 
markers
Resistance types 
of Candida spp.
Number (%) 
of isolates
0 259 (96.28%) 0 94 (75.20%)
1 ITR  4 (1.48%) 1
FCA
ITR
VRC
 2 (1.6%) 
 21 (16.8%)
 1 (0.80%)
2 FCA, ITR  1 (0.37%) 2 FCA, ITR  1 (0.80%)
3 FCA, ITR, VRC  5(1.85%) 3 FCA, ITR, VRC
AMB, FCA, ITR
 4 (3.20%)
 1 (0.80%)
4 AMB, FCA, 
ITR, VRC  1 (0.80%)
Total number 269 (100%) Total number 125 (100%)22
Resistance to fluconazole in Candida albicans was established in 2.23 % 
and 7.20% of Candida spp. Resistance to voriconazole was found in 1.85% C. 
albicans and 4.80% Candida spp. No resistance to amphotericin B was found 
in Candida albicans and in Candida spp., it was rare (1.60%).
From the blood isolates 24 (80%) were sensitive to all drugs tested (all 
strains of Candida albicans were completely sensitive) and from 20% resist-
ant isolates of Candida spp., 3 were identified as C. parapsilosis-1 isolate and 
C. tropicalis -2 isolates (10%), had 1 resistance marker and were resistant to 
itraconazole; 2 isolates of C. kruzei (6.66%) had 2 markers – fluconazole and 
itraconazole; and 1 C. tropicalis (3.33%) was resistant to 3 antimycotics – flu-
conazole, itraconazole and voriconazole (Table 2).
Tab. 2 – Resistance types of Candida isolates from blood (comparative data for Candida albicans 
and Candida spp.)
Number of 
resistance 
markers
Resistance types 
of Candida 
albicans
Number 
of isolates
Number of re-
sistance markers
Resistance types 
of Candida spp.
Number of 
isolates
0  6  0  18 
1   1 ITR  
 3 
 
2 2 FCA, ITR  2 
3 3 FCA, ITR, VRC  1 
Total number  6  Total number  24 
Candida albicans remains the most susceptible. All the isolates were 
susceptible to flucytosine and in isolates from blood no resistance to ampho-
tericine B was found, and in fecal isolates it was rare. Cross-resistance to 
azoles was found in the total of 16 isolates (3.77%), and it was more common 
in Candida spp. (6.71%) than in C. albicans (1.81%).
Twelve isolates were multiple resistant.
Resistance to itraconazole was dominant in both fecal and blood isolates, 
38 (9.64%) strains from fecal samples and 6 (20%) strains from blood were 
resistant to that drug (Graph 1). Isolates resistant to itraconazole were more often 
found in blood than in feces, the difference is statistically significant (p<0.01).
 Non-albicans Candida species were significantly (p<0.05) more fre-
quently resistant to itraconazole and fluconazole than Candida albicans. To 
itraconazole were resistant 10 from 275 (3.63%) C. albicans and 33 from 149 
Candida spp. (22.14%) (p<0.05). Resistance to fluconazole was less common 
in both groups of isolates, 6 from 275 C. albicans (2.18%) and 12 from 149 
Candida spp. (8.05%) (p<0.05). Overall resistance to itraconazole in 424 iso-
lates was 10.37% of isolates, to fluconazole 4.24% and to voriconazole 2.83%.23
Graph 1. Total number of resistant Candida isolates from blood and feces
0
2 3
15
6
38
1
11
0
5
10
15
20
25
30
35
40
AMB FCA ITR VRC
Candida from blood samples
Candida from fecal samples
DISCUSSION
Candida spp. is a member of physiological flora of the human skin and 
mucosal membranes. The prevalence of Candida colonization of the gastroin-
testinal tract in healthy people is very high (Ta sic  S. et al. 2008). There is a 
balance between Candida spp. of normal flora and immune defense mecha-
nisms, when this balance is disturbed colonization usually results in infection 
(Babic  M, Hu k ic  M. 2010). Rates of candidemia have increased over the 
past few decades causing the morbidity and mortality for immunocompromised 
patients, such as those with cancer or AIDS (Safd a r  A. et al., 2002). This 
analysis included clinical isolates from bloodstream and from feces, as the most 
Candida infections arise from the hosts’ endogenous microflora.
Our susceptibility results are similar to other studies: resistance is un-
common among C. albicans, and there is higher level of reduced susceptibil-
ity among non-albicans Candida spp. 
All the isolates studied were susceptible to flucytosine, and decreased 
susceptibility to amphotericin B was found only in fecal isolates of non-albi-
cans strains (1.60%) and resistance of all isolates tested was 0.47% that is 
consistent with reports from Spain, Turkey, and Mexico (F lor ez  C. et al., 
2008, Tu lu mog lu  S. et al. 2009, G on z a le s  GM. et al. 2008).24
The occurrence of azole cross-resistance in clinical C. albicans isolates 
has been demonstrated by German authors (Muel le r  F, M. et al., 2000) in 
children with HIV (human immunodeficiency virus). In our study, cross-re-
sistance to azoles was found in 16 isolates (3.77%), and it was more common 
in Candida spp. (6.71%) than in C. albicans (1.81%). In a study from Glasgow, 
UK, none of the blood culture isolates was resistant to either fluconazole or 
itraconazole (Ke n ne dy  H. F. et al., 2006).
Resistance to fluconazole in this study was found in 4.24% of all isolates 
tested, very similar to 4.1% found in Spain (F lor ez  C. et al., 2009) and less 
common than 15% seen in Portugal (C ost a- de - Ol iv ie r a  S. et al., 
2008). 
Overall resistance to itraconazole in 424 isolates was 10.37% of isolates; 
it was more common in Candida spp. (22.14%) than in C. albicans (3.63%). 
These results are higher than in Spain and Turkey (F lor ez  C. et al., 2009, 
Tu l u m o g l u  S.) but lower than 24.7% in Lithuania (S k r o d e n i e n e  E. et 
al., 2006), 27.6% in Venezuela (Pa n i z o  M. M. et al., 2009) and 43.3% in 
Mexico (G on z a le s  G. M. et al., 2008).
Overall resistance to voriconazole in this investigation was low (2.83%) 
especially in C. albicans (1.81%) which is consistent to the studies in which 
this drug displayed potent antifungal activity (Tor t or a no  A. M. et al., 
2006 and Q u i ndos  G. et al., 2008).
In conclusion, this study shows that in Novi Sad, Vojvodina, resistant 
isolates were found both in C. albicans and in Candida spp. and reduced sus-
ceptibility was documented in blood as well as in fecal isolates.
Reduced susceptibility to azoles was relatively rare; most commonly 
found in all isolates was the resistance to itraconazole. Isolates resistant to 
itraconazole were more often found in blood than in feces, the difference is 
statistically  significant.  Non-albicans  Candida  species  were  significantly 
more frequently resistant to itraconazole and fluconazole than Candida albi-
cans.
Voriconazole and amphotericine B were found to be very active against 
all species of Candida. Hence, these agents should be used in empirical treat-
ment for candidemia rather than fluconazole and itraconazole. 
Although resistance to antifungal agents of Candida spp. is rare at present, 
continued surveillance of antifungal susceptibility is necessary in order to 
monitor trends, and to choose the right empiric therapy.
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ОСЕТЉИВОСТ НА АНТИМИКОТИКЕ ИЗОЛАТА CANDIDA SPP. 
ИЗ КРВИ И ФЕЦЕСА ПРИКЉУЧЕНИХ У НОВОМ САДУ У 
ТРОГОДИШЊЕМ ПЕРИОДУ (2008-2010)
Јелесић З. Зора, Медић Д. Деана, Михајловић-Укропина М. Мира, Јевтић Марија, 
Гусман П. Вера, Радосављевић Ј. Биљана, Милосављевић Т. Биљана
Институт за јавно здравље Војводине, Нови Сад
Rezime
Кандидемија је значајна и све чешћа нозокомијална инфекција код паци  је-
на  та са факторима ризика. Candida врста пореклом из нестерилних подручја 
може да укаже на карактеристике сојева који узрокују инвазивну болест.
Циљ овог испитивања био је да се утврди осетљивост сојева Candida из крви 
и фецеса изолованих у Новом Саду, у Војводини. 
У току трогодишњег периода, од 2008. до 2010. године, прикупљено је 424 
изолата Candida spp., 30 изолата из крви и 394 сојева пореклом из узорака фецеса. 
Осетљивост ових изолата in vitro на пет антимикотика утврђено је коришћењем 
комерцијалног теста ATB FUNGUS 3 (BioMérieux).
Најчешћа врста била је Candida albicans (6 изолата из крви и 269 из фецеса). 
Резистенција на један или више антимикотика била је ређа код Candida albicans 
(3.63%) у односу на друге non-albicans врсте (24.83%). Резистенција је најчешће 
била изражена на итраконазол код обе испитиване групе, утврђена је код 9.64% 
сојева пореклом из фецеса и 20% изолата из крви. Мултипла резистенција на три 
или више антимикотика доказана је код дванаест изолата, углавном на флуко-
на  зол, итраконазол и вориконазол. Резистенција на амфотерицин Б била је врло 
ретка.
Иако је резистенција Candida spp. на антимикотике код нас засад ретка по-
јава, потребно је континуирано праћење и истраживање њихове осетљивости у 
циљу праћења трендова у појави резистентних изолата, али и због избора праве 
емпиријске терапије.